EGFR突变的晚期非小细胞肺癌的抗PD-1/PD-L1治疗研究进展

Research Progress of Anti-PD-1/PD-L1 Therapy for Non-small Cell Lung Cancer with EGFR Mutation

表皮生长因子受体(epidermal growth factor receptor,EGFR)酪氨酸激酶抑制剂(tyrosine kinase inhibitor,TKI)是EGFR突变的晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)的一线治疗方案,但1年-2年内会出现耐药,后续治疗效果差。程序性死亡受体1(programmed cell death 1,PD-1)/程序性死亡配体1(programmed cell death ligand 1,PD-L1)抑制剂的出现极大地改变了肿瘤治疗的格局。然而,单药抗PD-1/PD-L1对EGFR突变的晚期NSCLC低应答或无应答,如何使EGFR突变的晚期NSCLC患者从抗PD-1/PD-L1治疗中获益是需要攻克的难关。本文主要就近5年来EGFR突变对NSCLC免疫状态影响的研究进展及相关的临床研究进行综述。

The use of epidermal growth factor receptor(EGFR)tyrosine kinase inhibitor(TKI)is the first line treatment for EGFR-mutant advanced non-small cell lung cancer(NSCLC),but drug resistance will be acquired within 1-2 years,and the following treatment efficacy is poor.The invention of programmed cell death 1(PD-1)/programmed cell death ligand 1(PD-L1)inhibitors has dramatically changed the situation of tumor treatment.PD-1/PD-L1 inhibitors are less effective in patients with NSCLC harboring EGFR mutation.It is a challenge to make patients with EGFR-mutated advanced NSCLC benefit from anti-PD-1/PD-L1 therapy.In this paper,the research progress on the impact of EGFR mutation on the immune status of NSCLC and related clinical studies in recent 5 years are reviewed.